Drug Discovery
ByHow Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at JPM 2026 with a Radioligand Peptide Program Acquisition?
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM 2026 with an $840 Million Dark Blue Therapeutics Acquisition?
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
